Ser396

Site Information
RGELIPIsPSTEFGG SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 449253

In vivo Characterization
Methods used to characterize site in vivo:	[32P] bio-synthetic labeling ( 2 ) , immunoprecipitation ( 2 ) , mass spectrometry ( 1 ) , mutation of modification site ( 2 ) , peptide sequencing ( 2 ) , phosphoamino acid analysis ( 2 )
Relevant cell line - cell type - tissue:	BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 1 ) , COS (fibroblast) ( 2 ) , HEK293T (epithelial) ( 2 )

Upstream Regulation
Kinases, in vitro:	CDK2 (mouse) ( 2 )

References
1	Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 32 28852199 Curated Info
2	Johnson TK, Schweppe RE, Septer J, Lewis RE (1999) Phosphorylation of B-Myb regulates its transactivation potential and DNA binding. J Biol Chem 274, 36741-9 10593981 Curated Info